

**Thursday, 10. February 2022***Physicians Session*

14:00 - 14:15

A1

**OP01 - Opening***Chair:* Nicolaus Kröger, DE*Chair:* John Gribben, GB*EBMT/EHA on-demand [Pre-recorded session]*

14:00 - 20:30

OD

**YA01 - EBMT Trainee Committee & YoungEHA Ambassadors***Chair:* Claire Horgan, GB*Chair:* Eleni Gavriilaki, GR

YA-1	<b>Science for the future: The basic science behind the cure</b> <i>Speaker:</i> Michael Hudecek, DE	14:00 - 14:16
YA-2	<b>What is real in the real world? A balanced walk through the data jungle: Current indications, trial Vs real world data, the importance of reporting</b> <i>Speaker:</i> Anna Sureda, ES	14:16 - 14:31
YA-3	<b>Infused, what now? How to learn to detect and treat adverse events: CRS &amp; ICANS</b> <i>Speaker:</i> Roberta Di Blasi, FR	14:31 - 14:53
YAQ	<b>Closing remarks</b>	14:53 - 14:57

*Physicians Session*

14:15 - 15:15

A1

**PS01 - Session 1 - Clinical Indications***Chair:* Thomas Cluzeau, FR*Chair:* Claire Roddie, GB

PS01-1	<b>Approved and emerging CAR-Ts in ALL</b> <i>Speaker:</i> Mohamad Mohty, FR	14:15 - 14:27
PS01-2	<b>Approved and Emerging CARTs in Non-Hodgkin's Lymphoma</b> <i>Speaker:</i> Anna Sureda, ES	14:27 - 14:39
PS01-3	<b>Emerging CAR-Ts in CLL</b> <i>Speaker:</i> John Gribben, GB	14:39 - 14:51
PS01-4	<b>Approved and emerging CAR-Ts in MM</b> <i>Speaker:</i> Hermann Einsele, DE	14:51 - 15:03
PS01Q	<b>Q&amp;A</b>	15:03 - 15:15

*Physicians Session*

15:25 - 16:25

A1

**PS02 - Session 2 - New Clinical Data and Trial Pipeline***Chair:* Fabio Ciceri, IT*Chair:* Annette Künkele, DE

<b>CD19 and GD2 CAR T in Pediatric Cancer</b>	15:25 - 15:37
---	---------------

PS02-1	<i>Speaker:</i> Franco Locatelli, IT	
PS02-2	<b>Factors associated with outcomes of CD19-targeted immunotherapy</b> <i>Speaker:</i> Cameron Turtle, US	15:37 - 15:49
PS02-3	<b>Update from 'HCB' CAR T trials</b> <i>Speaker:</i> Julio Delgado, ES	15:49 - 16:01
PS02-4	<b>Update from 'UKW' CAR T trials</b> <i>Speaker:</i> Michael Hudecek, DE	16:01 - 16:13
PS02Q	<b>Q&amp;A</b>	16:13 - 16:25

*Best Abstracts*

16:30 - 17:00

A1

**BA01 - Best abstracts & Awards***Chair:* John Gribben, GB*Chair:* Nicolaus Kröger, DE

BA01-1	<b>Discovery of Synthetic Cell States for Cancer Immunotherapy</b> <i>Speaker:</i> Franziska Blaeschke, US	16:30 - 16:35
BA01-2	<b>Microbial Short-chain Fatty Acids Enhance CAR T Cell-mediated Cancer Immunotherapy</b> <i>Speaker:</i> Maik Luu, DE	16:35 - 16:40
BA01-3	<b>Tumor-on-a-Chip for Efficacy and Safety Assessment of CAR-T Cell Therapy</b> <i>Speaker:</i> Tengku Ibrahim Maulana, DE	16:40 - 16:45
BA01Q	<b>Q&amp;A</b>	16:45 - 17:00

*Break*

17:00 - 17:30

A1

**B1 - Break, Poster Viewing, Visit Exhibition***Keynote*

17:30 - 18:15

A1

**KN01 - Keynote Lecture 1***Chair:* Sonia Guedan, ES*Chair:* Michael Loschi, FR

KN01-1	<b>CAR T update and charting a way forward</b> <i>Speaker:</i> Carl June, US	17:30 - 18:00
KN01Q	<b>Q&amp;A</b>	18:00 - 18:15

*Satellite Symposium*

18:30 - 19:15

A1

**SS01 - Satellite symposium by Janssen | Transforming the landscape of multiple myeloma with CAR T-cell therapies***Chair:* Philippe Moreau, FR

	<b>Introduction</b>	18:30 - 18:32
	<i>Speaker:</i> Philippe Moreau, FR	
SS01-2	<b>How are CAR T-cell therapies changing the landscape in multiple myeloma?</b>	18:32 - 18:47
	<i>Speaker:</i> Kwee Yong, GB	
SS02-3	<b>Practical considerations for CAR T-cell therapy in patients with multiple myeloma</b>	18:47 - 19:02
	<i>Speaker:</i> Inger Nijhof, NL	
	<b>Panel discussion with Q&amp;A</b>	19:02 - 19:15
<i>Virtual Poster Tours</i>		
19:20 - 19:50		A1
<b>PT01 - Virtual Poster Tour 1   Pre-clinical Data</b>		
<i>Chair:</i> Michael Hudecek, DE		
PT01-1	<b>Multi-antigen-Targeting of MM Using TCR and CAR Engineered T Cells</b>	19:20 - 19:23
	<i>Oral Presenter:</i> Tassilo L A Wachsmann, NL	
PT01-2	<b>Ribonucleoprotein-mediated CRISPR Prime Editing Enables Precision Editing in Primary T-cells</b>	19:23 - 19:26
	<i>Oral Presenter:</i> Karl Petri, US	
PT01-3	<b>CARAMBA</b>	19:26 - 19:29
	<i>Oral Presenter:</i> Elisabeth Ehrend, DE	
PT01-4	<b>CAR T-cells Targeting Aspergillus fumigatus</b>	19:29 - 19:32
	<i>Oral Presenter:</i> Michelle Seif, DE	
PT01-5	<b>Functional Activity of CIK Cells Plus Blinatumomab and CARCIK-CD19 Cells</b>	19:32 - 19:35
	<i>Oral Presenter:</i> Silvia Zaninelli, IT	
PT01Q	<b>Q&amp;A</b>	19:35 - 19:50
<i>Virtual Poster Tours</i>		
19:20 - 19:50		A2
<b>PT02 - Virtual Poster Tour 2   Clinical data</b>		
<i>Chair:</i> Ibrahim Yakoub-Agha, FR		
PT02-1	<b>Superiority of Axicabtagene Ciloleucel in Second-line LBCL in the Elderly</b>	19:20 - 19:23
	<i>Oral Presenter:</i> Tom van Meerten, NL	
PT02-2	<b>Molecular CAR-T Cell Tracking in Real-world Patients with Severe ICANS</b>	19:23 - 19:26
	<i>Oral Presenter:</i> Susanna Carolina Berger, DE	
PT02-3	<b>CAR-HEMATOTOX: Risk-stratifying Infectious Complications and Disease Progression in r/r LBCL</b>	19:26 - 19:29
	<i>Oral Presenter:</i> Kai Rejeski, DE	

PT02-4	<b>Prophylactic Corticosteroids with Axi-Cel in R/R LBCL: ZUMA-1 Cohort 6</b> <i>Oral Presenter:</i> Olalekan O. Oluwole, US	19:29 - 19:32
PT02-5	<b>Healthcare Decision-making in Patients with DLBCL: CAR-T vs non-CAR-T</b> <i>Oral Presenter:</i> Lorna Warwick, CA	19:32 - 19:35
PT02Q	<b>Q&amp;A</b>	19:35 - 19:50

*Virtual Poster Tours*  
20:00 - 20:30

A1

### **PT03 - Virtual Poster Tour 3 | Pre-clinical Data**

*Chair:* Michael Hudecek, DE

PT03-1	<b>Multimodal Imaging of CAR T Cells in a Solid Tumor</b> <i>Poster Presenter:</i> Rita Pfeifer, DE	20:00 - 20:03
PT03-2	<b>PD-1/PD-L1 Axis in CAR-T Cell Function</b> <i>Poster Presenter:</i> Irene Andreu-Saumell, ES	20:03 - 20:06
PT03-3	<b>CXCR4-modified CD33.CAR-Clk with Enhanced Bone Marrow Homing in AML</b> <i>Poster Presenter:</i> Marta Biondi, IT	20:06 - 20:09
PT03-4	<b>Engineered T Cells Overcoming Rejection by Antibodies (CORA-T Cells)</b> <i>Poster Presenter:</i> Anna Christina Dragon, DE	20:09 - 20:12
PT03-5	<b>CAR-Tregs for Systemic Lupus Erythematosus</b> <i>Oral Presenter:</i> Matteo Doglio, IT	20:12 - 20:15
PT03Q	<b>Q&amp;A</b>	20:15 - 20:30

*Virtual Poster Tours*  
20:00 - 20:30

A2

### **PT04 - Virtual Poster Tour 4 | Clinical Data**

*Chair:* Ibrahim Yakoub-Agha, FR

PT04-1	<b>Sleeping Beauty-engineered CARClk-CD19 in B-ALL Patients</b> <i>Oral Presenter:</i> Chiara F. Magnani, CH	20:00 - 20:03
PT04-2	<b>CD19 CAR-T Cells with HPK1 Knockout Might Be Safe and Effective for Adult r/r B-ALL</b> <i>Oral Presenter:</i> Yu Wang, CN	20:03 - 20:06
PT04-3	<b>CARTITUDE-2 Cohort A Update: Ciltacabtagene Autoleucel in Progressive, Multiple Myeloma</b> <i>Oral Presenter:</i> Michel Delforge, BE	20:06 - 20:09
PT04-4	<b>Locally Produced Novel BCMA CART Cells</b> <i>Oral Presenter:</i> Nathalie Asherie, IL	20:09 - 20:12
PT04-5	<b>Patient and Caregiver Experiences of CAR-T at a UK Centre</b> <i>Oral Presenter:</i> Charlotte Stenson, GB	20:12 - 20:15

PT04Q

**Q&A**

20:15 - 20:30

**Friday, 11. February 2022***Keynote*

09:00 - 09:45

A1

**KN02 - Keynote Lecture 2***Chair:* Dirk Busch, DE*Chair:* Sara Mastaglio, ITKN02-1            **Strategies to increase tumor elimination with engineered T cells**            09:00 - 09:30*Speaker:* Stanley Riddell, USKN02Q            **Q&A**            09:30 - 09:45*Nurses Session*

09:00 - 09:10

A2

**OPN1 - Introduction & Welcome***Chair:* Michelle Kenyon, GB*Chair:* Erik Aerts, CH*Nurses Session*

09:10 - 09:40

A2

**NG00 - The Nice Experience***Chair:* Michelle Kenyon, GB*Chair:* Erik Aerts, CHNG00-1            **Introducing the CART programme into practice – the Nice experience**            09:10 - 09:30*Speaker:* Alizee Soldati, FRNG00Q            **Q&A**            09:30 - 09:40*Nurses Session*

09:45 - 10:50

A2

**NG01 - Nurses Session I - Overview***Chair:* Michelle Kenyon, GB*Chair:* Erik Aerts, CHNG01-1            **Overview of immune system and its role in fighting cancer**            09:45 - 10:03*Speaker:* Antonia Mueller, CHNG01-2            **Overview of clinical studies in haematological malignancies**            10:03 - 10:21*Speaker:* Adrian Bloor, GBNG01-3            **Paediatric indications and experience**            10:21 - 10:39*Speaker:* Daphna Hutt, ILNG01Q            **Q&A**            10:39 - 10:50

*Physicians Session*

09:50 - 10:50

A1

**PS03 - Session 3 - Next-Gen CAR-T Therapy***Chair:* Álvaro Urbano Ispizua, ES*Chair:* Chiara Bonini, IT

PS03-1	<b>Engineering Next-Generation CAR-T Cells for Cancer Therapy</b> <i>Speaker:</i> Yvonne Chen, US	09:50 - 10:02
PS03-2	<b>In vivo CAR T cell generation</b> <i>Speaker:</i> Christian Buchholz, DE	10:02 - 10:14
PS03-3	<b>iPSC-derived CAR-T cells: the road to clinical translation</b> <i>Speaker:</i> Maria Themeli, NL	10:14 - 10:26
PS03-4	<b>CAR-T therapy and the microbiome</b> <i>Speaker:</i> Christoph Stein-Thöringer, DE	10:26 - 10:38
PS03Q	<b>Q&amp;A</b>	10:38 - 10:50

*Break*

10:50 - 11:25

A1

**B2 - Break, Poster Viewing, Visit Exhibition***Industry Theatre*

10:50 - 11:20

A1

**IT02 - Industry Theatre (Auditorium 1): The Future of CART | by Novartis**

IT02-1	<b>Advancing Manufacturing process in CART</b> <i>Speaker:</i> Bernd Eschgfäller, CH	10:50 - 11:00
IT02-2	<b>The Next Generation of CART</b> <i>Speaker:</i> Aby Buchbinder, US	11:00 - 11:10
IT02-3	<b>Interactive Q&amp;A discussion</b>	11:10 - 11:20

*Nurses Session*

11:20 - 13:05

A2

**NG02 - Nurses Session II - Treatment Updates***Chair:* John Murray, GB*Chair:* Ruth Clout, GB

NG02-2	<b>CART in lymphoma</b> <i>Speaker:</i> Ulrich Jäger, AT	11:20 - 11:45
NG02-1	<b>CART in myeloma</b> <i>Speaker:</i> Maaïke de Ruijter, NL	11:45 - 12:05
NG02-3	<b>Off the shelf/Allo CART</b> <i>Speaker:</i> Jürgen Kuball, NL	12:05 - 12:25
NG02-4	<b>CART, IEC, BITE – what does the new technology mean for patients with solid malignancies</b> <i>Speaker:</i> Fiona Thistlethwaite, GB	12:25 - 12:45





*Speaker:* Dick Sundh, AU

*Satellite Symposium*

13:45 - 14:30

A1

**SS02 - Satellite symposium by Bristol Myers Squibb | CAR T cell therapy: current status and new perspectives**

*Chair:* Pere Barba, ES

SS02-1	<b>Welcome and Introduction</b>	13:45 - 13:50
SS02-2	<b>From innovation to implementation: CAR T for r/r LBCL</b> <i>Speaker:</i> Stephan Mielke, SE	13:50 - 14:05
SS02-3	<b>The future of cellular therapy in MM</b> <i>Speaker:</i> Salomon Manier, FR	14:05 - 14:20
SS02Q	<b>Q&amp;A and discussion   All faculty, moderated by Pere Barba   Closing remarks</b>	14:20 - 14:30

*Nurses Session*

14:30 - 16:00

A2

**NG03 - Nurses Session III - Patient Experience**

*Chair:* Ruth Clout, GB

*Chair:* John Murray, GB

NG03-1	<b>Patient experience - interview</b> <i>Speaker:</i> Guy Bouguet, FR <i>Speaker:</i> Philippe Piedigrossi, IT	14:30 - 14:55
NG03-2	<b>The role of charities in patient care</b> <i>Speaker:</i> Kristina Modic, SI	14:55 - 15:07
NG03-3	<b>Working with the third sector to enhance patient care</b> <i>Speaker:</i> Andreas L.G. Reimann, DE	15:07 - 15:20
NG03-4	<b>What supportive care do patients need?</b> <i>Speaker:</i> Natacha Bolaños, ES	15:20 - 15:45
NG03Q	<b>Q&amp;A</b>	15:45 - 16:00

*Physicians Session*

14:35 - 15:35

A1

**PS05 - Session 5 - Interactive pros / cons**

*Chair:* Jürgen Kuball, NL

*Chair:* Martina Schuessler-Lenz, DE

*Chair:* Attilio Bondanza, GB

PS05-1	<b>Allo vs. Auto CAR-T: Auto</b> <i>Speaker:</i> Michael Schmitt, DE	14:35 - 14:40
PS05-2	<b>Allo vs. Auto CAR-T: Allo</b> <i>Speaker:</i> Reuben Benjamin, GB	14:40 - 14:45
PS05Q1	<b>Debate</b>	14:45 - 15:05

PS05-3	<b>What is the future of CAR T-cell production? Academic point-of-care (POC) vs. centralized industrial manufacturing   pro POC</b> <i>Speaker:</i> Ibrahim Yakoub-Agha, FR	15:05 - 15:10
PS05-4	<b>What is the future of CAR T-cell production? Academic point-of-care (POC) vs. centralized industrial manufacturing   pro CIM</b> <i>Speaker:</i> Ulrike Köhl, DE	15:10 - 15:15
PS05Q2	<b>Debate</b>	15:15 - 15:35

*Physicians Session*  
15:40 - 16:40

A1

**PS06 - Session 6 - New CAR-T Indications**

*Chair:* Michael Hudecek, DE

*Chair:* Raffaella Greco, IT

PS06-1	<b>In vivo CART therapy for fibrosis</b> <i>Speaker:</i> Jonathan Epstein, US	15:40 - 15:52
PS06-2	<b>CD19-Targeted CAR T Cells in Refractory Systemic Lupus Erythematosus</b> <i>Speaker:</i> Andreas Mackensen, DE	15:52 - 16:04
PS06-3	<b>Opportunities and challenges of immunotherapeutic approaches of HBV cure</b> <i>Speaker:</i> Ulrike Protzer, DE	16:04 - 16:16
PS06-4	<b>Engineering Specific T cells to Modulate Adverse Immune Responses: Driving CARs to BARs</b> <i>Speaker:</i> David Scott, US	16:16 - 16:28
PS06Q	<b>Q&amp;A</b>	16:28 - 16:40

*Break*  
16:00 - 16:30

A2

**NB - Break, Poster Viewing, Visit Exhibition**

*Nurses Session*  
16:30 - 17:50

A2

**NG04 - Nurses Session IV - Treatment outcome influencers**

*Chair:* Erik Aerts, CH

*Chair:* Michelle Kenyon, GB

NG04-1	<b>'Prehab to rehab' – optimising health and wellbeing</b> <i>Speaker:</i> Aimee Green, GB	16:30 - 16:50
NG04-2	<b>Training and education – how to fill the gaps by working together</b> <i>Speaker:</i> Julia Ruiz Pato, ES	16:50 - 17:10
NG04-3	<b>Late effects – expected and unexpected</b> <i>Speaker:</i> Patrick Hayden, IE	17:10 - 17:30
NG04-4	<b>Case study</b>	17:30 - 17:45

	<i>Speaker:</i> Daniela Beyer-Bontognali, CH	
NG04Q	<b>Q&amp;A</b>	17:45 - 17:50
<i>Break</i>		
	16:40 - 17:00	A1
<b>B4 - Break, Poster Viewing, Visit Exhibition</b>		
<i>Physicians Session</i>		
	17:00 - 17:45	A1
<b>PS07 - Session 7 - CAR-T: New Standard of Care in Lymphoma?</b>		
<i>Chair:</i> Christian Chabannon, FR		
<i>Chair:</i> Marie Jose Kersten, NL		
PS07-1	<b>Second line treatment in aggressive B-NHL: CAR-T or autologous transplant?</b>	17:00 - 17:15
	<i>Speaker:</i> Mehdi Hamadani, US	
PS07-2	<b>Round table</b>	17:15 - 17:45
	<i>Speaker:</i> Ulrich Jäger, AT	
	<i>Speaker:</i> Bertram Glass, DE	
	<i>Speaker:</i> Guy Bouguet, FR	
	<i>Speaker:</i> Anna Sureda, ES	
<i>Keynote</i>		
	17:50 - 19:10	A1
<b>KN03 - Panel Chairs &amp; Keynote Lecture 3</b>		
<i>Chair:</i> Ibrahim Yakoub-Agha, FR		
<i>Chair:</i> Michael Hudecek, DE		
<i>Chair:</i> Maria Themeli, NL		
<i>Chair:</i> Hermann Einsele, DE		
KN03-all	<b>Where do we stand and where do we go with CAR-T? Discussion</b>	17:50 - 18:20
	<i>Speaker:</i> Michel Sadelain, US	
KN03-1	<b>Antigen sensitivity of CAR T cells</b>	18:20 - 18:50
	<i>Speaker:</i> Michel Sadelain, US	
KN03Q	<b>Q&amp;A</b>	18:50 - 19:10
<i>Nurses Session</i>		
	17:55 - 18:05	A2
<b>NGCL - Closing remarks</b>		
<i>Chair:</i> Erik Aerts, CH		
<i>Chair:</i> Michelle Kenyon, GB		
<i>Physicians Session</i>		
	19:15 - 20:15	A1
<b>PA01 - Things you need to know about CAR T-cell therapy: talking about CAR-T cell therapy in lay language   Roundtable</b>		
<i>Chair:</i> Natacha Bolaños, ES		

---

PA01-1	<b>Clinician Perspective</b> <i>Speaker:</i> Marie Jose Kersten, NL <i>Speaker:</i> Yavor Pertov, BG	19:15 - 19:15
PA01-2	<b>Patient perspective</b> <i>Speaker:</i> Jonathan Clark, GB	19:15 - 19:15
PA01-3	<b>Nurse Perspective</b> <i>Speaker:</i> Mairéad Ní Chonghaile, IE	19:15 - 19:15
PA01-4	<b>Psychologist Perspective</b> <i>Speaker:</i> Surabhi Chaturvedi, GB	19:15 - 19:15

**Saturday, 12. February 2022***Physicians Session*

08:30 - 09:45

A1

**PS08 - Session 08 - Clinical management***Chair:* Marion Subklewe, DE*Chair:* Hans Scheurer, NL

PS08-1	<b>MAS/ICANS - CRS</b> <i>Speaker:</i> Claire Roddie, GB	08:30 - 08:47
PS08-2	<b>Cytopenia/Infections</b> <i>Speaker:</i> Max Topp, DE	08:47 - 09:04
PS08-3	<b>COVID-19 and CAR-T Therapy</b> <i>Speaker:</i> Arnon Nagler, IL	09:04 - 09:21
PS08-4	<b>Specific organ tox (Cardiac)</b> <i>Speaker:</i> Daniel Chen, GB	09:21 - 09:33
PS08Q	<b>Q&amp;A</b>	09:33 - 09:45

*Physicians Session*

08:30 - 09:45

A2

**PS09 - Session 09 - CAR T Technology Forum***Chair:* Javier Briones, ES*Chair:* Miriam Alb, DE

PS09-1	<b>Gene transfer and genomic safety</b> <i>Speaker:</i> Zoltán Ivics, DE	08:30 - 08:42
PS09-2	<b>Safety &amp; Efficacy Models for CAR-T</b> <i>Speaker:</i> Monica Casucci, IT	08:42 - 08:54
PS09-3	<b>Machine learning in single cell genomics</b> <i>Speaker:</i> Fabian Theis, DE	08:54 - 09:06
PS09-4	<b>T cell subset selection for CAR engineering</b> <i>Speaker:</i> Luca Gattinoni, DE	09:06 - 09:18
PS09D	<b>Debate</b>	09:18 - 09:45

*Satellite Symposium*

09:45 - 10:30

A1

**SS04 - Satellite Symposium by Gilead Kite on R/R DLBCL highlights in CAR T from ASH 2021, Implications for current 3L+ practice**

SS04-1	<b>Introduction to the symposium</b>	09:45 - 09:47
SS04-2	<b>What have we learned about the pivotal CAR T trials?</b> <i>Speaker:</i> Tanya Siddiqi, US	09:47 - 09:56
SS04-3	<b>What learnings are there in the real-world use of CAR T?</b> <i>Speaker:</i> Roch Houot, FR	09:56 - 10:09

SS04-4            **What were the other DLBCL highlights in CAR T from ASH?**            10:09 - 10:20  
*Speaker:* Sridhar Chaganti, GB

SS04Q            **Close**            10:20 - 10:23

*Break*

10:30 - 11:00

A1

**B5 - Break, Poster Viewing, Visit Exhibition**

*Physicians Session*

11:00 - 12:15

A1

**PS10 - Session 10 - How to set-up and run a CAR-T unit**

*Chair:* Ibrahim Yakoub-Agha, FR

*Chair:* Natacha Bolaños, ES

PS10-1            **How to set-up and run a CAR-T unit**            11:00 - 11:15  
*Speaker:* Fabio Ciceri, IT

PS10-2            **Patient communication**            11:15 - 11:30  
*Speaker:* Marie Jose Kersten, NL

PS10-3            **Academic production**            11:30 - 11:45  
*Speaker:* Halvard Bönig, DE

PS10-4            **Patient perspective**            11:45 - 12:00  
*Speaker:* Lorna Warwick, CA

PS10Q            **Q&A**            12:00 - 12:15

*Physicians Session*

11:00 - 12:15

A2

**PS11 - Session 11 - Biotech Forum**

*Chair:* Ulf Grawunder, CH

*Chair:* Michael Hudecek, DE

PS11-1            **The Inventor's Perspective: Delivering CAR-Ts to the market**            11:00 - 11:15  
*Speaker:* Ulf Grawunder, CH

PS11-2            **The Analysts' Perspective: The CAR-T Market by 2030**            11:15 - 11:30  
*Speaker:* Pemba Lahmo, IN  
*Speaker:* Rupali Chaudhary, IN

PS11-3            **Biotech showcase**            11:30 - 12:00  
*Speaker:* Armin Ehninger, DE  
*Speaker:* David Gilham, US  
*Speaker:* Ulf Grawunder, CH  
*Speaker:* Elisa Kieback, DE  
*Speaker:* Michael O'Dwyer, IE

PS11Q            **Q&A**            12:00 - 12:15

*Best Abstracts*

12:20 - 13:35

A1

**BA03 - Best abstracts flash talks***Chair:* Hermann Einsele, DE*Chair:* Maria Themeli, NL

BA03-1	<b>N-glycosylation Inhibition Reverts Immunosuppression by TME Cells</b> <i>Speaker:</i> Camilla Sirini, IT	12:20 - 12:25
BA03-2	<b>Gene-transfer Methodology and Target-antigen Density Determine Car T-cell Performance</b> <i>Speaker:</i> Leon Gehrke, DE	12:25 - 12:30
BA03-3	<b>Dual CAR-CIK Cells for the Targeting of AML</b> <i>Speaker:</i> Sarah Tettamanti, IT	12:30 - 12:35
BA03-4	<b>Characterization of Antigen-driven CAR-T Cell Dysfunction in a Mouse Model of Her2-positive Solid Tumors</b> <i>Speaker:</i> Paula Barbao, ES	12:35 - 12:40
BA03-5	<b>Anti-CD117 CAR T Cells for Acute Myeloid Leukemia</b> <i>Speaker:</i> Chiara F. Magnani, CH	12:40 - 12:45
BA03-6	<b>ARI-0001 CART19 Cells in Relapsed/Refractory CLL and Richter's Transformation</b> <i>Speaker:</i> Valentin Ortiz-Maldonado, ES	12:45 - 12:50
BA03-7	<b>AML Targeting via UniCAR T-cells</b> <i>Speaker:</i> Laura Volta, CH	12:50 - 12:55
BA03Q	<b>Q&amp;A</b>	12:55 - 13:35

*Physicians Session*

12:20 - 13:35

A2

**PS12 - Session 12 - Trial management***Chair:* Stephan Mielke, SE*Chair:* Annalisa Ruggeri, IT

PS12-1	<b>European trial landscape</b> <i>Speaker:</i> Álvaro Urbano Ispizua, ES	12:20 - 12:32
PS12-2	<b>Multinational trial experience</b> <i>Speaker:</i> Julia Beckmann, DE	12:32 - 12:44
PS12-3	<b>Standardization in CAR-T trials</b> <i>Speaker:</i> H�el�ene Negre, FR	12:44 - 12:56
PS12-4	<b>EBMT CAR-T Data base</b> <i>Speaker:</i> Christian Chabannon, FR	12:56 - 13:08
PS12-5	<b>EBMT &amp; EHA GoCART Initiative</b> <i>Speaker:</i> J�urgen Kuball, NL	13:08 - 13:20
PS12D	<b>Debate</b>	13:20 - 13:35

*Keynote*

13:45 - 14:30

A1

**KN04 - Keynote Lecture 4***Chair:* Anna Sureda, ES*Chair:* Elizabeth Macintyre, FRKN04-1            **CAR T Cells for Diffuse Midline Gliomas and Other Pediatric**            13:45 - 14:15  
**Solid Tumors***Speaker:* Crystal Mackall, USKN04Q            **Q&A**            14:15 - 14:30*Speaker:* Michael Hudecek, DE*Speaker:* Ibrahim Yakoub-Agha, FR*Physicians Session*

14:30 - 14:45

A1

**CLS - Closing remarks***Chair:* Ibrahim Yakoub-Agha, FR*Chair:* Michael Hudecek, DE